Doug Manion

Doug has 20 years’ experience in drug development. He is currently the Executive Vice President of Research and Development for Arena Pharmaceuticals, a publicly traded (ARNA, NASDAQ) company focused on immunotherapeutic and cardiovascular disease. Until January 2021, he was CEO of Kleo Pharmaceuticals, a private biotech company spun out of Yale University that was acquired by Biohaven Holdings (BHVN, NYSE). Previously, he was the Senior Vice President and Head of Specialty Development and Head of Japan and China R&D at Bristol Myers-Squibb (BMY.NYSE) until October 2016. He had leadership roles at BMS overseeing various therapeutic areas including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GlaxoSmithKline (GSK, NYSE). He started his career at DuPont Pharmaceuticals in 1997. He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa Canada and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School. He is also on the Board of Directors for Celleron Therapeutics, and Oxford UK based private company focused on immune oncology.